The Epidemic of NASH: Current and Emerging Management and Treatment Strategies

The Epidemic of NASH: Current and Emerging Management and Treatment Strategies is organized by National Association for Continuing Education (NACE).

Start Date: 05/15/2019
Expiration Date: 05/14/2020

Target Audience: 
Primary Care Physicians, Nurse Practitioners, Physician Assistants

Credit(s):
• 1.0 AMA PRA Category 1 Credit™
• 1.0 AANP Contact hour which includes 0.25 pharmacology hours

Estimated Time To Complete CME Activity: 1.0 hour

Summary:
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease. NAFLD includes nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and is associated with liver cancer. NAFLD is associated with diabetes, obesity, and hyperlipidemia, and is considered to be the hepatic manifestation of metabolic syndrome. NAFLD patients with advanced fibrosis are at increased risk for all-cause mortality as well as cardiovascular and cancer related mortality.

The prevalence of NAFLD has been increasing with the increasing prevalence of obesity, diabetes, and metabolic syndrome. This activity will examine the clinical characteristics of those at high risk for NAFLD, how to distinguish non-alcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH), and the available and emerging treatment options for patients with NASH.

This webcast was recorded live at Conversations in Primary Care 2019 and is being used with the permission of the presenters.

Learning Objectives:
After completing this program participants should be able to:
• Identify patients at high risk for nonalcoholic fatty liver disease (NAFLD)
• Distinguish non-alcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH) and understand how to stage the disease
• Implement ongoing evidence based general management of patients with NASH
• Describe the available and emerging treatment options for patients with NASH